Edition:
India

Trisha Roy

SmileDirectClub eyes controlled growth and profitability in 2020

5:07am IST

SmileDirectClub Inc said on Tuesday it is looking at a "controlled growth" in 2020 after the online dental company posted a bigger-than-expected loss as it spent more to market its teeth aligners.

UPDATE 2-SmileDirectClub eyes controlled growth and profitability in 2020

5:06am IST

Feb 25 SmileDirectClub Inc said on Tuesday it is looking at a "controlled growth" in 2020 after the online dental company posted a bigger-than-expected loss as it spent more to market its teeth aligners.

Esperion says cholesterol drug gets U.S. approval; eyes $10 per pill pricing

22 Feb 2020

Esperion Therapeutics Inc said on Friday that U.S. health regulators approved its cholesterol-lowering drug, making it the first non-statin treatment to be cleared for sale in the country in nearly 20 years.

Biogen gears up for potential launch of Alzheimer's drug

31 Jan 2020

Biogen Inc said on Thursday it was preparing for the launch of its experimental treatment for Alzheimer's as the drugmaker races to become the first to bring a treatment for the memory-robbing disease to market.

Abbott hits all-time high on quarterly revenue beat

22 Jan 2020

Abbott Laboratories Inc's shares rose to an all-time high on Wednesday after the device maker beat Wall Street estimates for quarterly sales on higher demand for its nutrition products and generic drugs.

U.S. FDA panel split over approval of Durect's non-opioid painkiller

17 Jan 2020

Independent experts on an FDA advisory panel on Thursday were split over the approval of Durect Corp's non-opioid painkiller to manage post-surgical pain.

Walgreens misses profit estimates on pharmacy weakness, shares fall 7%

09 Jan 2020

Walgreens Boots Alliance Inc's quarterly profit missed Wall Street estimates on Wednesday, hit by lower payments from insurers on drugs sold at its U.S. pharmacies, knocking back its shares and those of rival CVS Health Corp . | Video

Apellis' drug better than Soliris in improving hemoglobin levels in trial

07 Jan 2020

Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients' hemoglobin levels than market leader Alexion Pharmaceuticals Inc's Soliris.

Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels

07 Jan 2020

Jan 7 Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients' hemoglobin levels than Alexion Pharmaceuticals Inc's Soliris, in a late-stage study.

World News